Anti-cataract agent discovered

Article

An investigation, published in Inorganic Chemistry, has revealed that the reaction of pirenoxine (PRX) with selenite or calcium ions could be adapted as an anti-cataract agent.

An investigation, published in Inorganic Chemistry, has revealed that the reaction of pirenoxine (PRX) with selenite or calcium ions could be adapted as an anti-cataract agent. Seleneite and calcium ions have been associated with the formation of lens cataracts.

Dr Jiahn-Haur Liao, Institute of Biological Chemistry, Academia Sinica, Taiwan, ld the study that found theoretical evidence that the interactions most likely occur at the bezoquinone (ring I) π-system.

Isothermal titration calorimetry (ITC), UV and Nuclear magnetic resonance spectroscopy (NMR) were used to demonstrate that PRX can bind a maximum of six selenite anions.

Peripheral binding occurred first and was followed by the π−π interactions with the aromatic moiety. The calcium ions were chelated by the 3-carboxylate and 8-ketomine functional groups for calcium cation interaction.

The results could provide the foundation for further studies involving the use PRX as an anti-cataract agent.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.